Live Breaking News & Updates on Reliance clinical research program

Stay updated with breaking news from Reliance clinical research program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Sergio-traversa , Cedric-ogorman , Maged-shenouda , Tim-mccarthy , Securities-exchange , Goldman-sachs , Nasdaq , Prnewswire-relmada-therapeutics-inc , Reliance-clinical-research-program , Relmada-therapeutics-inc , Chief-executive-officer , Chief-financial-officer

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

New-york , United-states , Maged-shenouda , Tim-mccarthy , Cedric-ogorman , Sergio-traversa , Relmada-therapeutics-inc , Nasdaq , Reliance-clinical-research-program , Prnewswire-relmada-therapeutics-inc , Securities-exchange , Chief-executive-officer

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Miami , Florida , United-states , Coral-gables , American , Tim-mccarthy , American-society-of-clinical-psychopharmacology , Securities-exchange , Prnewswire-relmada-therapeutics-inc , Reliance-clinical-research-program , Relmada-therapeutics-inc , Nasdaq

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Tim-mccarthy , Fabiana-fedeli , Sergio-traversa , Cedric-ogorman , Relmada-therapeutics-inc , Securities-exchange , Nasdaq , Company-phase , Reliance-clinical-research-program , Company-board-of-directors , Relmada-therapeutics

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

United-kingdom , Tim-mccarthy , Sergio-traversa , Cedric-ogorman , Fabiana-fedeli , Company-board-of-directors , Relmada-therapeutics-inc , Nasdaq , Securities-exchange , Company-phase , Reliance-clinical-research-program , Relmada-therapeutics

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

CORAL GABLES, Fla., March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary an...

United-kingdom , Cedric-ogorman , Sergio-traversa , Fabiana-fedeli , Tim-mccarthy , Securities-exchange , Nasdaq , Relmada-therapeutics-inc , Company-board-of-directors , Reliance-clinical-research-program , Company-phase , Relmada-therapeutics

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Tim-mccarthy , Relmada-therapeutics-inc , Reliance-clinical-research-program , Prnewswire-relmada-therapeutics-inc , Securities-exchange , Company-to-host-conference-call , Nasdaq , Host-conference-call-today , Major-depressive-disorder , Montgomery-asberg-depression-rating-scale , Conference-call , Adjunctive-treatment

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Tim-mccarthy , Reliance-clinical-research-program , Relmada-therapeutics-inc , Prnewswire-relmada-therapeutics-inc , Securities-exchange , Nasdaq , Conference-call , Relmada-therapeutics , Private-securities-litigation-reform-act , Securities-act , Securities-exchange-act , Nc-

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Tim-mccarthy , Reliance-clinical-research-program , Relmada-therapeutics-inc , Prnewswire-relmada-therapeutics-inc , Securities-exchange , Nasdaq , Conference-call , Relmada-therapeutics , Private-securities-litigation-reform-act , Securities-act , Securities-exchange-act ,

Relmada Therapeutics (RLMD) Phase 3 RELIANCE III Trial for REL-1017 Did Not Achieve its Primary Endpoint

Relmada Therapeutics (RLMD) Phase 3 RELIANCE III Trial for REL-1017 Did Not Achieve its Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , Relmada-therapeutics-inc , Reliance-clinical-research-program , Securities-exchange , Harvard-medical-school , Nasdaq , Major-depressive-disorder , Montgomery-asberg-depression-rating-scale , Maurizio-fava , Massachusetts-general-hospital